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Background: The SH2B1 gene (Src-homology 2B adaptor protein 1 gene) is a solid candidate gene for obesity.
Large scale GWAS studies depicted markers in the vicinity of the gene; animal models suggest a potential relevance
for human body weight regulation.
Methods: We performed a mutation screen for variants in the SH2B1 coding sequence in 95 extremely obese
children and adolescents. Detected variants were genotyped in independent childhood and adult study groups (up
to 11,406 obese or overweight individuals and 4,568 controls). Functional implications on STAT3 mediated leptin
signalling of the detected variants were analyzed in vitro.
Results: We identified two new rare mutations and five known SNPs (rs147094247, rs7498665, rs60604881,
rs62037368 and rs62037369) in SH2B1. Mutation g.9483C/T leads to a non-synonymous, non-conservative exchange
in the beta (βThr656Ile) and gamma (γPro674Ser) splice variants of SH2B1. It was additionally detected in two of
11,206 (extremely) obese or overweight children, adolescents and adults, but not in 4,506 population-based normal-
weight or lean controls. The non-coding mutation g.10182C/A at the 3’ end of SH2B1 was only detected in three
obese individuals. For the non-synonymous SNP rs7498665 (Thr484Ala) we observed nominal over-transmission of
the previously described risk allele in 705 obesity trios (nominal p = 0.009, OR = 1.23) and an increased frequency of
the same allele in 359 cases compared to 429 controls (nominal p = 0.042, OR = 1.23). The obesity risk-alleles at
Thr484Ala and βThr656Ile/γPro674Ser had no effect on STAT3 mediated leptin receptor signalling in splice variants
β and γ.
Conclusion: The rare coding mutation βThr656Ile/γPro674Ser (g.9483C/T) in SH2B1 was exclusively detected in
overweight or obese individuals. Functional analyzes did not reveal impairments in leptin signalling for the mutated
SH2B1.
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A large-scale genome-wide association study (GWAS)
meta-analysis including a total of 249,796 individuals
of European ancestry confirmed 14 known obesity-
susceptibility loci and newly identified 18 genetic loci
associated with body mass index (BMI). One of the re-
identified single nucleotide polymorphisms (SNPs) is
located near the Src-homology 2B adaptor protein 1
(SH2B1) gene (rs7359397) [1]. Association with obesity
was also shown for a coding SNP in SH2B1 (rs7498665:
g.8164A/G, Thr484Ala; [2,3]). Linkage disequilibrium
between rs7359397 and the coding SNP rs7498665 is
high (r2 = 0.965, D’ = 1; HapMap, http://hapmap.ncbi.
nlm.nih.gov/). Both SNPs are located within a large link-
age disequilibrium (LD) block. A region of more than
500 kb upstream and 150 kb downstream of SH2B1 is
flanked by recombination peaks of 37 cM/Mb or 36 cM/
Mb, respectively (SNP Annotation and Proxy Search
SNAP, see Additional file 1: Figure S1). The association
of increased BMI with SH2B1 SNP (rs7359397 and
rs7498665) alleles has been robustly replicated in e.g. (i)
4,923 Swedish adults [4], (ii) in 12,462 individuals from
the German MONIKA/KORA study [5], and (iii) in
1,045 obese adults and 317 healthy lean individuals from
Belgium [6].
A deletion of ~200 kb covering SH2B1 was recently
shown to be associated with severe early-onset obesity
[7], whereas the corresponding reciprocal duplication
was associated with leanness [8]. Additionally, a larger
interspersed deletion extending through a 593 kb region
on chromosome 16p11.2-p12.2 covering SH2B1 has
been associated with developmental delay, feeding diffi-
culties, dysmorphic facial features, and obesity [9,10].
Bochukava et al. [7] screened the coding region of
SH2B1 for causal mutations by re-sequencing of 500
early onset severely obese children of the Genetics of
Obesity Study (GOOS). The investigators detected SNP
rs7498665 (Thr484Ala [7]); rare variants were not identi-
fied. Evidence in humans and from animal models sug-
gests that SH2B1 is a likely obesity gene. In humans, the
SH2B1 protein increase serum leptin levels and whole
body fat mass in females [11]. The influence of SH2B1
variants on the distribution of body fat and the amount
of visceral adipose tissue is still under discussion
[4,12,13]. With regard to animal models, Sh2b1 null
mice show a phenotype of obesity, hyperlipidemia, leptin
resistance, hyperphagia, hyperglycaemia, insulin resist-
ance and glucose intolerance [14]. This phenotype was
consistent when the knockout was regionally limited to
hypothalamic neurons [15] and functionally limited to
induced mutations in the Src-homology 2 (SH2) and
pleckstrin homology (PH) domains [16]. Selective rescue
in neurons eliminated both obesity and the insulin re-
sistance phenotype [16]. Additional evidence for aninvolvement of Sh2b1 in the regulation of energy
homeostasis is derived from expression analyses in mice
and rats. In DIO (diet-induced obese) rats, fed a high fat
diet, the expression of Sh2b1 in hypothalamus was
decreased [17], while in mice on a high fat and high
carbohydrate diet, Sh2b1 expression increased in the
same tissue [18].
We initially detected transmission disequilibrium for a
SNP in the vicinity of SH2B1 (rs2008514) in 705 obesity
trios (p =0.0094 of TDT). The SNP is a proxy of
rs7359397, which lit up in large scale GWAS [1]. We
screened the coding region of SH2B1 for (infrequent)
mutations in 95 extremely obese children and adoles-
cents. For the GWAS-derived gene for type 2 diabetes
mellitus melatonin receptor 1B (MTNR1B) it was re-
cently shown that a number of rare to infrequent muta-
tions can be detected in the respective patients [19]. In
addition, based on the evidence for involvement of
SH2B1 in energy homeostasis, rare coding variants in
the gene could potentially result in monogenic obesity.
Subsequently, we assessed association of the identified
variants to obesity in independent study groups. In vitro
analyzes of the impact on leptin receptor signalling for
the detected variants ensued.
Material & methods
Study groups
An overview of the ten study groups is given in Table 1,
details have been described previously [20,21]. The selec-
tion of individuals for the mutation screen was based on
genotypes at SNP rs2008514 (proxy of rs7359397) in the
vicinity of SH2B1. In total, we analyzed 95 individuals,
90 of whom were likely enriched for the presence of
mutations in SH2B1. The other five individuals are
heterozygous carriers of a deletion at chr16p11.2 which
does not harbor SH2B1 [10]. These extremely obese
patients (offspring) from the family-based GWAS
sample were homozygous for the risk allele T of
rs2008514 and had at least one heterozygous parent,
thus substantially contributing to the observed over-
transmission of the rs2008514 T-allele. Association
to obesity of detected variants was analyzed in three
steps (Figure 1):
i. Association testing: All detected variants were
genotyped in a sample of 179 extremely obese
(age- and sex-adjusted BMI percentile ≥ 99th; [22])
children or adolescents and 185 lean adult
(age- and sex-adjusted BMI percentile < 15th; [22])
controls. Basic phenotypical characteristics are given
in Table 1. Individuals were independent of the
mutation screening sample and were part of our
case–control GWAS sample (Genome-Wide Human
SNP Array 6.0, see [20,21]).
Table 1 Phenotypic description of analyzed study groups
Samplea status n % male [%] age [mean ± SD] BMI [mean ± SD] BMI SDSb [mean ± SD]
Mutation Screen Cases 95 48.42 13.43 ± 3.37 31.87 ± 5.04 4.10 ± 1.71
SI: family-based GWAS Cases 705 45.11 13.44 ± 3.02 32.02 ± 5.82 4.23 ± 1.96
Parents 1,410 50.00 42.54 ± 6.02 30.28 ± 6.33 1.65 ± 1.84
SII: case–control GWAS Cases 453 42.60 14.37 ± 3.75 33.15 ± 6.68 4.51 ± 2.15
Controls 435 39.08 26.08 ± 5.75 18.09 ± 1.14 −1.45 ± 0.34
SIII: subset of case–control GWAS
(for association testing)
Cases 179 49.16 14.27 ± 2.39 35.56 ± 6.13 5.3 ± 2.09
Controls 185 55.68 25.56 ± 3.94 18.39 ± 1.09 −1.47 ± 0.33
SIV: obese adults Cases 988 37.25 47.17 ± 14.23 35.70 ± 5.43 3.22 ± 1.66
SV: DAPOC Cases 1,185 44.22 10.72 ± 2.78 27.69 ± 5.11 3.07 ± 1.56
SVI: KORA Cases 6.633 56,43 56.62 ± 13.13 29.42 ± 3.70 1.19 ± 1.09
Controls 3.444 36,76 47.18 ± 13.37 22.72 ± 1.68 −0.53 ± 0.51
SVII: Ulm children’s study 1 Cases 97 57.73 7.57 ± 0.42 20.68 ± 1.71 1.06 ± 0.46
Controls 685 54.31 7.56 ± 0.42 15.63 ± 1.38 −0.25 ± 0.37
SVIII: BEPOC Cases 1,046 47.99 10.89 ± 3.57 29.46 ± 5.91 3.54 ± 1.82
SIX: Ulm children’s study 2 Cases 271 51.29 11.07 ± 3.69 29.75 ± 6.04 3.62 ± 1.88
SX: Ulm children’s study 3 Cases 129 43.41 14.90 ± 1.84 40.45 ± 8.00 7.05 ± 2.92
aMutation Screen sample: part of the family-based and the case–control GWAS samples’ cases; Family-based GWAS sample: 705 index patients with early-onset
extreme obesity and their biological parent; case–control GWAS sample: GWAS of early-onset extremely obese children and adolescents in comparison to lean,
adult controls; case–control sample for association testing: early-onset extremely obese children and adolescents in comparison to lean, adult controls;
independent of initial screening sample; subset of cases-control GWAS sample; DAPOC: Datteln Paediatric Obese Cohort (27); KORA: Cooperative Health Research
in the Region of Augsburg (30); Ulm children’s study 1: Ulm Research on Metabolism, Exercise and Lifestyle in Children (31); BEPOC: Berlin Paediatric Obese Cohort
(28); Ulm children’s study 2 and 3: Ulm Paediatric Obese Cohort A and B (INSULA) (29).
bCalculation of the BMI SDS values has been based on population reference values following the National Nutrition Survey I (25).
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The three non-synonymous variants (rs147094247:
g.2749C/A - Thr175Asp; rs7498665: g.8164A/G -
Thr484Ala; g.9483C/T - βThr656Ile/γPro674Ser)
were additionally genotyped in the remaining
individuals of the family-based sample and the
cases and controls of our GWAS sample, who
were not screened for mutations (see Mutation
Screen section) and in 988 obese adults [23] as
well as in 1,185 independent obese children or
adolescents of the ‘Datteln Paediatric Obese
Cohort’ (DAPOC [24]; Table 1).
iii. Additional exploration of rare non-synonymous
variants: The two coding mutations without
previously shown association to obesity βThr656Ile/
γPro674Ser and rs147094247 - Thr175Asp - were
additionally genotyped in three independent study
groups comprising obese children and adolescents
(‘Berlin Paediatric Obese Cohort’ — BEPOC;
n = 1,046 [25]; Ulm Children's Study 2 and 3;
n = 271 and 129, respectively [26]; Table 1) and in
two independent population-based cohorts, the
‘Cooperative Health Research in the Region of
Augsburg’ (KORA; n = 10,077 [27]) cohort of adults,
and the ‘Ulm Children's Study 1’ (n = 782 [28]) study
group of children and adolescents (Table 1).In all samples, body mass index (BMI in kg/m2) was
assessed and age- and sex-specific percentile criteria with
regard to the German population at the time of sample re-
cruitment (SI, SII, SIII, SIV, SVI [22]) were used to define
overweight or obese cases. Samples were divided into cases
(adults: BMI ≥ 25, children and adolescents: ≥ 90th BMI
percentile (www.mybmi.de)) and controls (adults: BMI ≤
25, children and adolescents: BMI ≤ 90th percentile
(www.mybmi.de)). Written informed consent was given
by all participants and in case of minors by their par-
ents. These studies were approved by the Ethics Com-
mittees of the respective Universities and Institutions
and were performed in accordance with the Declaration
of Helsinki.
Mutation screen
The coding region of SH2B1, located at chr16: 28,858,010
- 28,885,533 (hg18/ NCBI 36), was screened for mutations
by denaturating high pressure liquid chromatography
(dHPLC, WAVE, Transgenomics) as described previously
[29]. Accuracy of dHPLC is similar or even higher than
sequencing [30]. To enhance the sensitivity of detection of
homozygous mutation carriers, DNA of an individual with
wild type genotype (re-sequenced) was added to each
sample prior to PCR amplification. All samples with
deviant dHPLC patters were re-sequenced. Detailed
Figure 1 Flow chart for experimental setup. GWAS:
genome-wide association study; SNP: single nucleotide
polymorphism; dHPLC: denaturating high performance liquid
chromatography; DAPOC: Datteln Paediatric Obese Cohort
(Reinehr et al. 2007); KORA: Cooperative Health Research in the
Region of Augsburg (Wichmann et al. 2005); Ulm children’s
study 1: Ulm Research on Metabolism, Exercise and Lifestyle in
Children (Nagel et al. 2009); BEPOC: Berlin Paediatric Obese
Cohort (Bau et al. 2009); Ulm children’s study 2 and 3: Ulm
Paediatric Obese Cohort A and B (INSULA) (Wabitsch et al. 2004).
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mers for PCR and dHPLC analysis can be obtained
from the authors. All PCR amplicons with dHPLC
patterns deviant from the wild-type pattern were re-
sequenced as described previously [31]. At least two
experienced individuals independently assigned the
genotypes; discrepancies were solved either by reach-
ing consensus or by re-genotyping.Genotyping
The identified variants in SH2B1 were genotyped in lar-
ger study groups using either restriction fragment length
polymorphism (RFLP) or TaqMan Assays (detailed in-
formation can be obtained from the authors). For
rs147094247 (Thr175Asp) and the new coding mutation in
fragment 9 (g.9483C/T βThr656Ile/γPro674Ser), custom
TaqMan assays were designed (SH2B1_2I_MUT, Assay ID:
AHCS0BY, and Frag9_mut1, Assay ID: AHMSHDX, re-
spectively, both Applied Biosystems). At least two experi-
enced individuals independently assigned the genotypes;
discrepancies were solved either by reaching consensus or
by re-genotyping.
Statistics
Allele and genotype distributions of all detected variants
did not deviate from Hardy-Weinberg equilibrium. To
analyze the obesity association of all variants, Fisher’s
exact test (allelic association) was calculated with PLINK
[32]. Population-based samples were divided into cases
(BMI ≥ 90th percentile) and controls (BMI < 90th percen-
tile). For rs7498665 an asymptotic, 2-tailed p-value for
the transmission disequilibrium test (TDT) was add-
itionally calculated with PLINK. If not stated otherwise,
all p-values are asymptotic, two-sided and not corrected
for multiple testing.
Functional in silico analyzes
To determine the potential alteration in gene expression,
all mutations were analyzed for loss or gain of cryptic
splice sites, transcription factor binding sites and gain or
loss of o-glycosilation sites. Prediction of possible impact
of amino acid exchange on structure and function of
SH2B1 was done by PolyPhen-2 [33], SNAP [34], PMUT
[35], and MutationTaster [36]. Detailed description of
used tools can be found in the Additional file 1: Supple-
mentary materials. Conservation was analyzed by align-
ing sequences of 21 species in total (21 α, eight β and
six γ sequences, comprehensive list in Additional file 1:
Supplementary materials).
Functional in vitro analyzes: STAT3 mediated leptin
receptor signalling
The effect of SH2B1 harboring the infrequent alleles of
Thr484Ala and βThr656Ile/γPro674Ser on leptin recep-
tor activity was determined with a quantitative reporter
gene assay (adapted from [37]). HEK293 cells were tran-
siently transfected with the murine long form of the lep-
tin receptor (Lepr-b) in pcDNA3.1, a signal transducer
and activator of transcription 3 (STAT3) responsive Pho-
tinus luciferase construct (pAH32), a constitutive Renilla
luciferase expression vector for data normalization
(phRG-b, Promega) and human SH2B1 splice variants
beta and gamma with and without the mutations in
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kindly provided by Rosenblum et al. [37]). For control
empty pcDNA3 expression vector was transfected in-
stead of SH2B1. After stimulation with mouse leptin
(concentrations 0, 0.5, 1, 5 , 10, 50, 100, 500 ng/ml), the
STAT3 reporter construct led to luciferase expression
measured with the Dual–Luciferase Reporter Assay sys-
tem according to manufactures’ instruction (Promega).
Dose–response curves, EC50 and Emax values were cal-
culated by Graph Pad Prism.
Results and discussion
We performed a mutation screen of the coding region of
SH2B1 in 95 extremely obese children and adolescents.
We identified two unknown mutations and five known
SNPs in SH2B1 (Table 2). All detected variants were fol-
lowed up in a small, independent case–control sample,
only non-synonymous variants were additionally geno-
typed in further independent study groups.
New infrequent variant βThr656Ile/γPro674Ser
A new mutation at position g.9483 (C/T) of SH2B1 results
in a non-synonymous, non-conservative exchange in two
of the three human splice variants (β and γ) of SH2B1.
Due to a shifted reading frame for the two splice variants,
the mutation results in two different non-synonymous,
non-conservative exchanges (βThr656Ile or γPro674Ser)
in the β or γ splice variants, respectively. The βThr656Ile/
γPro674Ser mutation was not detected in an independent
sample of 179 extremely obese cases and 185 lean con-
trols. As the mutation resulted in a non-synonymous
amino acid exchange which was predicted to change pro-
tein structure (Table 3), we additionally genotyped a total
of 11,029 (extremely) obese or overweight children,
adolescents and adults and 4,321 controls (for children





11 12 22 Minor allele
frequency
cases [%]
g.2749C/A rs147094247 Thr175Asp 11, 257 11 0 0.05
g.8164A/G rs7498665 Thr484Ala 512 1,526 1,101 40.62
g.8250C/T rs60604881 70 87 22 36.59
g.8738A/G rs62037368 176 2 0 0.56
g.8764C/T rs62037369 65 81 32 40.73
g.9483C/T βThr656Ile,
γPro674Ser
11,206 2 0 0.01
g.10182C/A 178 1 0 0.28
a genotyped in 3,230 obese cases and 439 lean controls.
b genotyped in a total of 179 obese cases and 185 lean controls.
c genotyped in a total of 11,406 obese and overweight cases and 4,568 (mainly pop
d Odds ratio is given with respect to the minor allele.25kg/m2) for this mutation. We detected two additional
obese cases with this mutation and no mutation carrier
among the controls. The extremely low frequency of the
mutation limits the determination of an association to
overweight and obesity (p = 1; Table 2). We calculated that
the control group would need to include more than
545,757 individuals to reveal a p-value below 0.05 with
statistical power above 80%, if the observed trend (only
mutation carriers among the overweight or obese indivi-
duals) would remain stable. Both risk alleles (T-allele at
g.9483C/T and G-allele at rs7498665) are potentially
located on the same haplotype (as determined in one
index patient and his mother who transmitted the haplo-
type; for the other carriers, full genotype information of
both parents was not available). A founder effect of this
mutation is likely.
All three detected βThr656Ile/γPro674Ser mutation
carriers are female. The initially identified mutation car-
rier (a) of the screening sample (height 163 cm, weight
86.2 kg, BMI 32.44 kg/m2, age 12.7 years) as well as one
mutation carrier (b) from the follow-up samples (height
142 cm, weight 53.2 kg, BMI 26.38 kg/m2, age 9.9 years)
had a BMI > 99th percentile. In both cases, the over-
weight or obese mother (BMI 25.76 kg/m2 and 32.61 kg/
m2, respectively) transmitted the mutation to the ex-
tremely obese child. The third mutation carrier (c) had a
BMI > 90th percentile (height 130 cm, weight 31.5 kg,
BMI 18.64 kg/m2, age 7.2 years). For this mutation car-
rier, genotypic information about the parents was not
available (mother BMI 19.81 kg/m2, father BMI 26.7 kg/
m2). Insulin levels were only available for one mutation
carrier (b), whose level was in the normal range (9.4
mU/l). Additional family members were not available.
The amino acid exchanges in the β and γ splice variants
(βThr656Ile/γPro674Ser) are located outside the domain
structure (self-dimerization, Pleckstrin-homology and SH2tations in SH2B1 excluding the screening group
Genotypes controls










4,511 1 0 0.01 4.4 0.57 - 34.13 0.199c
58 195 181 35.83 1.2 1.06-1.42 0.007a
73 75 37 40.27 0.86 0.63 - 1.15 0.323b
182 3 0 0.81 0.69 0.11 - 4.16 1b
79 82 23 34.78 1.29 0.95 - 1.74 0.107b
4,506 0 0 0.00 NA NA 1c
184 0 0 0.00 NA NA 0.493b
ulation based) controls.
Table 3 In silico prediction of splice sites, transcription factor binding sites and o-glycosylation sites of detected
variants in SH2B1











rs147094247 Thr175Asp g.2749C/A changed changed not changed not changed not changed 33.1829
rs7498665 Thr484Ala g.8164A/G changed changed not changed not changed not changed —
rs60604881 — g.8250C/T changed SRp40,
FOX1-FOX2a
not changed not changed not changed —
rs62037368 — g.8738A/G changed not changed not changed not changed COUP-TF, c-REL b —





g.9483C/T changed not changed not changed GATA1, GATA2 b not changed 53.5329
g.10182C/A — g.10182C/A changed PESS a not changed not changed not changed —
a particular changed predicted splice sites, b particular changed predicted transcription factor binding sites.
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SH2B1. We analyzed the impact of the variant rare allele
of βThr656Ile/γPro674Ser on leptin signalling in vitro via
the STAT3 pathway. In both splice variants, β656Ile or
γ674Ser showed unaltered leptin signalling (Figure 2, Add-
itional file 1: Table S2).
While the γPro674Ser exchange in the γ splice variant is
predicted to be neutral by in silico programs, the exchange
of βThr656Ile in the β splice variant was predicted to be
“not neutral” (SNAP), “pathological” (PMUT) or “disease
causing” (Mutation taster) in three of four programs
(Additional file 1: Table S1). The exchange in the β splice
variant would also destroy a predicted O-glycosylation site
of the SH2B1 protein. Amino acid conservation wasFigure 2 Leptin receptor activity measured by STAT3 mediated lucife
transfected with LEPRb, a STAT3 responsive element and SH2B1 splice varia
alleles at rs7498665 (Thr484Ala) and βThr656Ile/γPro674Ser. The dose respo
(exact values for each data point see Additional file 1: Table S2).strong on both positions (86% for βThr656Ile and 100%
for γPro674Ser, Additional file 1: Table S1).
Previous in vitro data showed functional differences
between β and γ SH2B1 variants: (a) It has been shown
that the β splice variant is mainly expressed in the hypo-
thalamus [16], a brain region known to be implicated in
weight regulation. A Sh2b1β rescue was sufficient to
prevent the Sh2b1 knockout phenotype in mice [19].
Leptin signalling is mediated by the interaction of
SH2B1β and JAK2 [17]. The β splice variant of SH2B1
recruits insulin receptor substrates 1 and 2 (IRS1 and 2)
to the LEPRb/JAK2 complex [38]. SH2B1β enhances JAK2
activity and promotes the activation of several down-
stream networks like STAT3 and phosphatidylinositol (PI)rase response. HEK293 cells (n = 8 separate experiments) were co-
nts beta (left) and gamma (right) with and without the infrequent
nse curves depict leptin receptor activity after stimulation with leptin
Volckmar et al. BMC Medical Genomics 2012, 5:65 Page 7 of 10
http://www.biomedcentral.com/1755-8794/5/653-kinase pathways [18,39]. Two in silico analyzes predicted
an altered folding or function of SH2B1 βThr656Ile (Add-
itional file 1: Table S1). (b) The γ splice variant of SH2B1
is peripherally expressed. It interacts with Tyr1158 in the
activation loop of the insulin receptor and prohibits
dephosphorylation of IRS1 and IRS2 [40]. This interaction
enhances insulin signalling and insulin receptor auto-
phosphorylation, leading in turn to activation of down-
stream pathways [41]. While the three tyrosine motifs in
the N-terminal part of SH2B1, which regulate interaction
with the insulin receptor [42], are not directly affected by
this exchange, it is possible that altered protein folding
due to an non-conservative amino acid exchange in a
highly conserved position prevents their phosphorylation.
Coding GWAS derived SNP rs7498665
We confirmed that the described risk allele G at SNP
rs7498665 [2,3] is associated with obesity in our 705
obesity trios (p = 0.009) and in a total of 3,139 independ-
ent cases and 434 controls (p = 0.007, odds ratio (OR) =
1.22, 95% confidence interval (CI) 1.06-1.42; Table 1).
This coding SNP results in the non-synonymous, non-
conservative amino acid exchange Thr484Ala in a slpice
variant independent position with low conservation (5%,
Additional file 1: Table S1). As the association with
obesity was previously described for this SNP, we did not
analyze further study groups (2–6). In vitro analyses
revealed unaltered leptin signalling via STAT3 in both
splice variants for the obesity risk allele at Thr484Ala
(Figure 2). Both Emax and EC50 were non-significantly
reduced (Figure 2, Additional file 1: Table S2).
Since the obesity risk allele at the GWAS derived poly-
morphism rs7498665 increases BMI by only approxi-
mately 0.15 BMI units (kg/m2) as calculated in a
population of 125,931 European individuals [1], we
expected only subtle functional alterations associated
with the minor allele of this variant.
Other genetic variants in SH2B1
The second newly detected mutation is located in the 3’
UTR at base pair position g.10182 (C/A). This non-
coding variant was detected twice within the screening
sample, and once in an obese case in the association
testing step (Figure 1). The variant showed no associ-
ation to obesity in a small case control comparison (p =
0.49; Table 2); in silico analyzes predicted a possible
change in splice sites for this variant (Table 3).
Results for the four other identified SNPs were as fol-
lows: The third coding SNP rs147094247 leads to a non-
synonymous, conservative exchange (Thr175Asp) at a
conserved position (71%, Additional file 1: Table S1). No
association to obesity (p = 0.199, odds ratio (OR) = 4.4,
95% confidence interval (CI) 0.57 - 34.13; Table 1) was
found for this SNP in a sample of 11,268 obese andoverweight cases and 4,512 lean or normal weight controls
(mostly population based). For the non-synonymous SNP
rs147094247 (Thr175Asp), in silico analyzes predict a neu-
tral outcome for the altered amino acid (Additional file 1:
Table S1).
For SNPs rs60604881 (p = 0.323, OR = 1.17, 95% CI =
0.87-1.58), rs62037368 (p = 1.00, OR = 1.45, 95% CI =
0.24-8.71) and rs62037369 (p = 0.107, OR = 1.29, 95%
CI = 0.95-1.74) evidence for association to early onset ex-
treme obesity could not be detected (Table 2). For all
SNPs in silico analyzes predict splice site or transcription
factor binding site changes (Table 3).
Leptin signalling
The assay that measured STAT3 mediated leptin re-
sponse successfully showed increased leptin response
after co-transfection with wild type SH2B1 splice var-
iants β and γ. This indicates that HEK293 cells and the
STAT3 assay allow functional characterization of SH2B1.
While in mice only the alpha splice variant was tested
for leptin signalling [43], we observe an effect on leptin
signalling for both other splice variants (β and γ) in our
human cell system (Figure 2, Additional file 1: Table S2).
The analysis of the impact of both SH2B1 variants on
leptin receptor activity showed no significant reduction
of STAT3 mediated signalling by the risk alleles at
rs7498665 and βThr656Ile/γPro674Ser. The non-
significant decrease in EC50 and Emax for both tested
variants in splice variants β and γ could indicate both
gain of function and reduced function; the biological im-
pact of both remains to be solved. If indeed a minor
functional effect would be present, a much larger num-
ber of replicates would be necessary to establish a sig-
nificant effect (e.g. about 2x270 replicates when using
the Emax point estimates of SH2B1γ vs. SH2B1γP674S
and their variances when applying Satterthwaite/Welch
t-Test aiming at 80% power for two-sided α = 5%). Our
results could, of course, indicate that the two variants
are not functionally relevant. However, for a polygenic
variant a large functional effect is rather unlikely. For ex-
ample, the melanocortin 4 receptor gene (MC4R), a well
known obesity gene, harbors two polymorphisms
(Val103Ile and Ile251Leu) that are negatively associated
with obesity [44,45]. Carriers of the minor alleles have a
BMI approx. 0.5 BMI units lower than wild type carriers
[44,45]. Initial in vitro assays did not show functional
implications for the minor alleles of these SNPs (e.g.
[44]), but when the number of different assays was
increased, in vitro tests showed potential small gain of
function for both minor alleles [46], which could explain
the weight lowering effect of the variant. Hence we
speculate that the functional effect of the analyzed
SH2B1 variants might become detectable when a battery
of different functional tests is applied. Currently we have
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slightly reduced function. In addition, with STAT3
mediated leptin signalling, we only tested one of the
many potential interaction partners of SH2B1 in regula-
tion of energy homeostasis. A potential additive effect of
small functional changes in leptinergic and insulinergic
signalling could result in stronger impact on body
weight maintenance.
Conclusion
A recent mutation screen in 300 children from the
GOOS cohort which display insulin resistance in
addition to obesity revealed three variants and one SNP
that showed an effect on cell differentiation and migra-
tion, but with the exception of the frameshift variant
Phe344fs no other functional deficiencies [47]. Compar-
able to our study, Doche et al. analyzed the impact of
detected variants on janus kinase 2 (JAK2) phosphoryl-
ation with additional tests of insulin receptor substrate 2
(IRS2) phosphorylation and SH2B1 dimerization [47].
Given the low frequency of βThr656Ile/γPro674Ser
(g.9483C/T), this mutation cannot explain our positive
TDT for rs2008514 with obesity. Adding the three rare
mutations detected by Doche et al. which show low func-
tional impact still leaves a large proportion of BMI associ-
ation inexplicable [47]. The region around SH2B1 on chr
16p11.2 shows low recombination rates for approximately
1Mb (chr16:28,177,800 shows a recombination peak of
37cM/Mb and chr16:28,944,400 a recombination peak of
36 cM/Mb; HapMap, http://hapmap.ncbi.nlm.nih.gov/),
implicating a large region with high linkage disequilib-
rium. The area tagged by both BMI associated SNPs
(rs7498665 and rs7359397 [1-3]) covers 17 genes (com-
pare Additional file 1: Figure S1). Hence, relevant muta-
tions in one of the remaining 16 genes might account for
a larger proportion of the GWAS results. Alternatively,
genetic variation outside of the SH2B1 coding region with
a regulatory effect on this gene explains the association in
functional terms. Guo et al. recently showed an intronic
SNP in SH2B1 (rs4788099) which regulated mRNA
expression of nearby genes Tu translation elongation fac-
tor, mitochondrial (TUFM), coiled-coil domain containing
101 (CCDC101), Homo sapiens spinster homolog 1
(SPNS1), sulfotransferase family, cytosolic, 1A, phenol-pre-
ferring, member 1 (SULT1A1) and sulfotransferase family,
cytosolic, 1A, phenol-preferring, member 4 (SULT1A4) in B
cells and monocytes [48]. This is in concordance with
findings by Gutierrez-Aguilar et al. who reported differen-
tial regulation of Sh2b1, Tufm and Sult1a1 in rats fed a
high fat diet [17].
In conclusion, the rare allele of the variant βThr656Ile/
γPro674Ser in SH2B1 was found exclusively in three over-
weight or obese children but not in normal-weight or
underweight controls. Our findings suggest that this newrare mutation predisposes to increased BMI, possibly
related to decreased leptin signalling. Further studies are
warranted to investigate the functional impact of the mu-
tation for both affected splice variants on the interaction
of SH2B1 effector systems (e.g. leptin and insulin recep-
tors), which play a major role in energy homeostasis.
Additional file
Additional file 1: Table 1. In silico functional prediction of detected
non-synonymous mutations in SH2B1. Table 2: Parameters of leptin
receptor activity measured by STAT3 mediated luciferase response.
Figure 1: Identified variants in the three splice variants (α, β and γ) of
human SH2B1. SH2B1 mRNA – coding parts as filled blocks – (Ensembl
sequences α: ENST00000322610, β: ENST00000359285 and γ:
ENST00000337120). The domain structure (Quian and Ginty 2001) with
dimerization, Pleckstrin homology and SH2 domain is shown as
underlying grey boxes. Positions of detected variants are marked with
lines. Available rs-numbers, if applicable amino acid exchanges and minor
allele frequencies in obese cases (MAF according to Table 1) are given
for each variant. Supplementary material: In silico analysis tool description.
Supplementary Figure 2: Regional association and linkage disequilibrium
plot of 1000 genome project data centered to SNP rs7498665 (http://
www.525broadinstitute.org/mpg/snap/). Displayed are recombination
rate (blue), r² to rs7498665 (range of grey, increased intensity shows
higher linkage) and genes in region. Dashed lines mark a region in high
LD (r² > 0.8) with rs7498665. Gene abbreviations: EIF3CL/EIF3C (eukaryotic
translation initiation factor 3), CLN3 (ceroid-lipofuscinosis, neuronal 3),
APOB48R (apolipoprotein B48 receptor), IL27 (interleukin 27), NUPR1 (p8
protein isoform a), CCDC101 (coiled-coil domain containing 101), SULT1A1
(sulfotransferase family, cytosolic, 1A, member 1), SULT1A2
(sulfotransferase family, cytosolic, 1A,member 2), ATXN2L (ataxin 2 related
protein isoform C), TUFM (Tu translation elongation factor, mitochondrial),
SH2B1 (SH2B adaptor protein 1 isoform 1), ATP2A1 (ATPase, Ca++
transporting, fast twitch 1 isoform), RABEP2 (rabaptin, RAB GTPase binding
effector protein 2), CD19 (CD19 antigen precursor), NFATC2IP (Nuclear
factor of activated T-cells, cytoplasmic 2-interacting protein), SPNS1
(spinster homolog 1 isoform 1), LAT (linker for activation of T cells isoform
b). Figure 3: Conservation in C-terminal sequences of SH2B1 splice
variants (β and γ). Boxes mark the position of exchange g.9483C/T
(βThr656Ile/γPro674Ser) in β and γ splice variants in several species.
Abbrevations
BEPOC: Berlin Paediatric Obese Cohort; BMI: Body mass index;
CCDC101: Coiled-coil domain containing 101; DAPOC: Datteln Paediatric
Obese Cohort; DHPLC: Denaturating high performance liquid
chromatography; DIO: Diet induced obese; GWAS: Genome-wide association
study; GOOS: Genetics of Obesity Study; IRS2: Insulin receptor substrate 2;
JAK2: Janus kinase 2; KORA: Cooperative Health Research in the Region of
Augsburg; LEPRB: Long form of the leptin receptor; MC4R: Melanocortin 4
receptor; MTNR1B: Melatonin receptor 1b; PCR: Polymerase chain reaction;
PH: Pleckstrin homology; RFLP: Restriction fragment length polymorphism;
SH2B1: Src-Homology 2B adaptor protein 1; SH2: Src-homology 2;
SNP: Single nucleotide polymorphism; SPNS1: Homo sapiens spinster
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member 1; SULT1A4: Sulfotransferase family, cytosolic, 1A, phenol-preferring,
member 4; STAT3: Signal transducer and activator of transcription 3;
TDT: Transmission disequilibrium test; TUFM: Tu translation elongation factor,
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